Dechra Pharmaceuticals (DPH) Reaches New 12-Month High at $2,794.00

Dechra Pharmaceuticals (LON:DPH) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 2,794 ($39.22) and last traded at GBX 2,766 ($38.83), with a volume of 371692 shares changing hands. The stock had previously closed at GBX 2,766 ($38.83).

A number of equities research analysts have recently issued reports on the stock. Jefferies Group upgraded shares of Dechra Pharmaceuticals to a “buy” rating and lifted their price target for the company from GBX 2,221 ($31.18) to GBX 2,631 ($36.93) in a research report on Tuesday, January 30th. Numis Securities reiterated an “add” rating and set a GBX 2,640 ($37.06) price target on shares of Dechra Pharmaceuticals in a research report on Monday, February 26th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a GBX 2,400 ($33.69) price target on shares of Dechra Pharmaceuticals in a research report on Monday, February 26th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Dechra Pharmaceuticals has an average rating of “Buy” and an average target price of GBX 2,121.17 ($29.77).

The firm also recently disclosed a dividend, which was paid on Friday, April 6th. Stockholders of record on Thursday, March 8th were paid a dividend of GBX 7.33 ($0.10) per share. The ex-dividend date was Thursday, March 8th. This represents a dividend yield of 0.29%.

TRADEMARK VIOLATION WARNING: “Dechra Pharmaceuticals (DPH) Reaches New 12-Month High at $2,794.00” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at

About Dechra Pharmaceuticals

Dechra Pharmaceuticals plc develops, manufactures, sells, and markets veterinary pharmaceuticals and related products for veterinarians worldwide. The company operates through the European Pharmaceuticals, the North American Pharmaceuticals, and the Pharmaceuticals Research and Development segments. It offers various endocrinology, dermatology and care, anesthesia and analgesia, cardiovascular disease, ophthalmology, and equine medicine products; food producing animal antimicrobials; poultry vaccines; and pet diets.

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply